PSilocybin for psYCHological and existential distress in PALliative care (PSYCHED-PAL): A single arm unblinded clinical trial.
A clinical trial found that microdose psilocybin was safe and feasible in palliative care, with 69% of participants reporting meaningful global improvement and 72% showing significant reductions in demoralization — suggesting it may offer a scalable, low-risk option for existential and psychological distress near the end of life.
A two-centre Canadian clinical trial testing microdose psilocybin in 20 adults with advanced, incurable illness and severe psychological distress, most with a prognosis of 1-12 months. Participants received escalating daily oral doses over three weeks (1mg, 2mg, then 3mg). No serious adverse events were reported. Of the 13 who completed the intervention, 69% reported meaningful global improvement, 62% reported over 50% improvement in depression scores, 54% in anxiety scores, and 72% in demoralization scores.
Read the study →










